Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrphostin Ag 490 SCHEMBL93683 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL29351367 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL29379893 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL17743575 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL93682 | 1.00 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7378564 | 0.88 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin Ag 490 SCHEMBL2279211 | 0.88 | EGFR (0.77) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Ls-104 SCHEMBL3956490 | 0.86 | MAOB (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL645291 | 0.86 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Ls-104 SCHEMBL3956495 | 0.86 | MAOB (1.00) | EGFRMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180460-B2 | Amino pyrimidine derivatives | NOVARTIS AG (CH) | 2021-11-23 | — | — | US | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-10751339-B2 | Substituted aminopyrimidine compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-08-25 | — | — | US | disclosed |
| US-20190224197-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-07-25 | — | — | US | disclosed |
| EP-3046563-B1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS PI3-KINASE INHIBITORS | CALITOR SCIENCES LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-10106604-B2 | Method of treating auto-inflammatory syndromes with IL-1beta antibodies related to canakinumab | NOVARTIS AG (CH) | 2018-10-23 | — | — | US | disclosed |
| US-9670194-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9657007-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170073411-A1 | Methods of Treating Kawasaki Disease Using IL-1b Antibodies | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-9518046-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2016-12-13 | — | — | US | disclosed |
| US-9168298-B2 | Methods of treating vascular disease using an IL-1beta Antibody | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-20150087658-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087663-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| WO-2015042077-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | WO | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20130309241-A1 | Methods of Treating Vascular Disease using IL-1beta Antagonists | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8524667-B2 | Methods of treating gout using IL-1BETA antibodies | NOVARTIS AG (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20130072396-A1 | Transplant Rejection Markers | NOVARTIS AG (CH) | 2013-03-21 | — | — | US | disclosed |
| US-20120321642-A1 | Methods of Treating Gout using IL-1beta Antagonists | NOVARTIS AG (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120321642-A1 | Methods of Treating Gout using IL-1beta Antagonists | IL1RN, IL1R1, IL1B | EGFR 4119/4885MEN1 2848/4885KMT2A 3661/4885 |
| US-20150087663-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | EGFR 1064/4885MEN1 4654/4885KMT2A 1010/4885 |
| US-20190224197-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3R1, PIK3R3 | EGFR 702/4885MEN1 4526/4885KMT2A 995/4885 |
| US-10751339-B2 | Substituted aminopyrimidine compounds and methods of use | PIK3CA, PIK3CD, MYD88 | EGFR 1063/4885MEN1 4666/4885KMT2A 960/4885 |
| US-20130309241-A1 | Methods of Treating Vascular Disease using IL-1beta Antagonists | IL1RN, IL1R1, IL1A | EGFR 2192/4885MEN1 2108/4885KMT2A 2946/4885 |
| US-11180460-B2 | Amino pyrimidine derivatives | BTK, LCK, JAK1 | EGFR 452/4885MEN1 4865/4885KMT2A 1083/4885 |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | EGFR 1329/4885MEN1 2254/4885KMT2A 2743/4885 |
| US-20170073411-A1 | Methods of Treating Kawasaki Disease Using IL-1b Antibodies | IL1RN, IL1R1, IL1B | EGFR 2161/4885MEN1 2225/4885KMT2A 2698/4885 |
| US-20150087658-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | EGFR 1063/4885MEN1 4666/4885KMT2A 960/4885 |
| US-10106604-B2 | Method of treating auto-inflammatory syndromes with IL-1beta antibodies related to canakinumab | IL1RN, IL1B, IL1R1 | EGFR 2209/4885MEN1 3059/4885KMT2A 4161/4885 |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | UGT2B7, NAT1, CYP2B6 | EGFR 587/4885MEN1 3015/4885KMT2A 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.